Journal
JOURNAL OF CELLULAR PHYSIOLOGY
Volume 227, Issue 7, Pages 2818-2821Publisher
WILEY
DOI: 10.1002/jcp.23038
Keywords
-
Categories
Funding
- Scientific Research Program of Shanghai [11ZR142400]
- Funding of Xinhua Hospital [11QYJ010]
Ask authors/readers for more resources
Phosphatidylinositol 3-kinase (PI3K), one member of lipid kinase family, has been demonstrated to play a key role in regulating cell proliferation, adhesion, survival, and motility. Recent studies indicate that PI3K related signaling pathway is one of the most commonly activated pathways in human cancers. Accordingly, pharmacological inhibition of key nodes in this signaling cascade has been a focus in developmental therapeutics. To date, Inhibitors targeting PI3K or nodes in this pathway, AKT and mTOR, are best studied and have reached clinical trials. In this review, we will focus on recent progress on understanding of PI3Ks signaling pathway and the development of PI3K inhibitors. J. Cell. Physiol. 227: 28182821, 2012. (C) 2011 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available